Clark Estates Inc. NY Buys New Shares in IQVIA Holdings Inc. (NYSE:IQV)

Clark Estates Inc. NY acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 95,200 shares of the medical research company's stock, valued at approximately $16,784,000. IQVIA accounts for about 3.6% of Clark Estates Inc. NY's holdings, making the stock its 9th largest holding. Clark Estates Inc. NY owned 0.05% of IQVIA as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. American National Bank & Trust acquired a new stake in shares of IQVIA in the first quarter worth $26,000. Golden State Wealth Management LLC increased its position in shares of IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after acquiring an additional 130 shares in the last quarter. AllSquare Wealth Management LLC acquired a new stake in shares of IQVIA in the first quarter worth $33,000. ST Germain D J Co. Inc. increased its position in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares in the last quarter. Finally, GKV Capital Management Co. Inc. acquired a new stake in shares of IQVIA in the fourth quarter worth $39,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analysts Set New Price Targets

IQV has been the subject of several recent research reports. William Blair reissued an "outperform" rating on shares of IQVIA in a research report on Wednesday, July 23rd. JPMorgan Chase & Co. lowered their price target on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a report on Monday, May 19th. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. UBS Group raised their price objective on shares of IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Finally, Robert W. Baird raised their price objective on shares of IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. Seven research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $228.62.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

IQVIA Stock Down 1.8%

IQV stock traded down $3.42 during trading hours on Friday, hitting $182.44. The company's stock had a trading volume of 1,644,130 shares, compared to its average volume of 2,034,876. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The company has a market capitalization of $31.01 billion, a PE ratio of 26.40, a price-to-earnings-growth ratio of 2.10 and a beta of 1.30. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $252.88. The stock has a 50 day moving average price of $161.20 and a two-hundred day moving average price of $170.18.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. The company had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.64 earnings per share. On average, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.